Viking Therapeutics (VKTX) Azione Prezzo

Viking Therapeutics Prezzo

NASDAQ·CHIUSO
26,72
​
Mercato chiuso

Il margine netto di Viking Therapeutics si attesta al -513.877,3%, in calo rispetto al -368.045,8% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 95,00 USD, ovvero il 255,5% sopra il prezzo attuale. Su 27 analisti, 24 valutano il titolo come acquisto — nel complesso un consenso Acquistare.

Viking Therapeutics Prezzo delle azioni

Accedi a questi dati tramite l’API Eulerpool

100.000 richieste/mese gratis · nessuna carta di credito

Viking Therapeutics Azione e analisi azionaria

Viking Therapeutics Inc. è una società biotecnologica specializzata nello sviluppo di farmaci per il trattamento dei disturbi metabolici ed endocrini. Fondata nel 2012 da Brian Lian, Ph.D., ha sede a San Diego, in California. Il modello di business dell'azienda si concentra sul targeting dei recettori della bile X (LXR) per il trattamento delle malattie metaboliche. Viking Therapeutics mira a sviluppare opzioni terapeutiche per la steatosi epatica non alcolica (NAFLD) e la steatoepatite non alcolica (NASH), nonché per l'osteoporosi e l'ipotiroidismo. I prodotti principali in fase di sviluppo sono VK2809 per NAFLD/NASH e VK5211 per l'osteoporosi. La società vanta un promettente portafoglio di prodotti e mira a migliorare la vita di milioni di pazienti.

Domande frequenti sull'azione Viking Therapeutics

The business model of Viking Therapeutics Inc revolves around developing novel therapeutics for metabolic and endocrine disorders. The company focuses on researching and developing small molecule drugs that target specific biological pathways to address conditions such as non-alcoholic steatohepatitis (NASH), hip fracture recovery, and other metabolic diseases. Viking Therapeutics aims to provide innovative solutions to unmet medical needs by advancing its pipeline of drug candidates through rigorous scientific research and clinical trials. By leveraging its expertise in drug discovery and development, Viking Therapeutics strives to improve the lives of patients and deliver value to its stakeholders.

Viking Therapeutics Inc is primarily active in the pharmaceutical industry, specifically focusing on the development of novel therapies for metabolic and endocrine disorders. With a strong emphasis on addressing unmet medical needs, Viking Therapeutics aims to provide innovative solutions for patients suffering from conditions like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Through their extensive research and development efforts, Viking Therapeutics is committed to improving the lives of individuals affected by these diseases.

The main competitors of Viking Therapeutics Inc in the market include Amgen Inc, Intercept Pharmaceuticals Inc, and Gilead Sciences Inc.

Viking Therapeutics Inc is a biopharmaceutical company specializing in the development of novel therapies for metabolic and endocrine disorders. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California. The company is dedicated to advancing its pipeline of innovative drug candidates, aiming to address the significant unmet medical needs in areas like non-alcoholic steatohepatitis (NASH) and hip fracture recovery. Viking Therapeutics' research focuses on the role of specific receptors in modulating metabolic and hormonal pathways, targeting diseases that affect millions worldwide. With a strong commitment to scientific excellence, Viking Therapeutics strives to deliver groundbreaking treatments to improve patient outcomes and quality of life.

Viking Therapeutics Inc has achieved several significant milestones. Firstly, the company successfully completed Phase 2 clinical trials for its lead product candidate VK2809, demonstrating its potential to treat fatty liver disease. Additionally, Viking Therapeutics received FDA orphan drug designation for VK2809 in the treatment of glycogen storage disease type Ia. The company also announced positive results from Phase 2 clinical trials for VK5211, a potential treatment for muscle loss. Viking Therapeutics' achievements demonstrate its dedication to advancing innovative therapies in areas of high unmet medical needs, making it a promising player in the pharmaceutical industry.

Viking Therapeutics Inc, a renowned pharmaceutical company, primarily operates in the United States. With a strong focus on the development of novel therapies for metabolic and endocrine disorders, Viking Therapeutics actively engages in clinical research and collaboration within the US market. By leveraging innovative approaches and strategic partnerships, Viking Therapeutics Inc aims to address critical medical needs and improve patients' lives. With its headquarters based in San Diego, California, Viking Therapeutics remains committed to advancing transformative treatments within the domestic pharmaceutical landscape.

Viking Therapeutics Inc represents values of innovation, integrity, and patient-centricity. As a biopharmaceutical company, Viking Therapeutics is committed to developing novel treatments for metabolic and endocrine disorders. The company's corporate philosophy emphasizes a research-driven approach, ensuring the highest quality in drug discovery and development. Viking strives for transparency and ethical practices in all aspects of its operations. With a focus on improving patients' lives through therapeutic advancements, Viking Therapeutics remains dedicated to revolutionizing the treatment options available in the healthcare industry.

Gli analisti fissano attualmente un prezzo obiettivo medio di 93,60 USD per l’azione Viking Therapeutics (mediana: 95,00 USD), pari a +250,3 % rispetto all’ultimo prezzo. Il consenso si basa su 27 giudizi di analisti.

27 analisti valutano attualmente l’azione Viking Therapeutics: 24 raccomandano l’acquisto, 3 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Viking Therapeutics ricavi pari a 7,17 Mio. USD e un utile per azione di -5,44 USD.

Convertita al tasso di cambio attuale, l’azione Viking Therapeutics quota 24,35 EUR (26,72 USD).

L’azione Viking Therapeutics (VKTX) è quotata su 6 borse, tra cui: NASDAQ (VKTX), London (0VQA.L), Frankfurt (1VT.F), München (1VT.MU), Düsseldorf (1VT.DU).

Viking Therapeutics Inc. is a biopharmaceutical company focused on the development of drugs for metabolic and endocrine diseases. The company was founded in 2012 and is headquartered in San Diego, California. Viking Therapeutics currently offers two main products: VK2809 and VK5211. VK2809 is a selective thyroid hormone receptor beta agonist developed for the treatment of fatty liver disease and hypercholesterolemia. VK5211 is a selective androgen receptor modulator used for the treatment of muscle wasting and weakness, as well as for supporting rehabilitation measures. Both VK2809 and VK5211 are still in various stages of clinical development and have shown promising results. In clinical studies, VK2809 has shown the ability to achieve significant improvements in liver function and cholesterol levels. VK5211 has also shown positive results in clinical studies by increasing muscle strength and mass in patients with muscle wasting. Viking Therapeutics has also entered into a research collaboration with Ligand Pharmaceuticals, a leading provider of ligand technology. The partnership aims to discover and develop additional potential drug candidates that address a broader range of diseases. The business model of Viking Therapeutics is based on the development and commercialization of new drugs targeting specific disease areas. The company uses an innovative scientific approach to develop potential therapies that build on existing biological processes in the body. These drugs are specifically tailored to the needs of patients with metabolic and endocrine disorders. In addition, Viking Therapeutics relies on careful selection of study centers for conducting clinical trials. The company selects centers that have extensive experience in clinical research and adhere to the strictest standards for conducting clinical trials. Viking Therapeutics primarily finances its research and development projects through equity and debt financing. As part of its business strategy, the company also seeks partnerships and licensing agreements with other companies to expand the distribution of its products and services. In summary, Viking Therapeutics' business model is focused on developing and marketing novel therapies for metabolic and endocrine diseases. Through collaboration with various research institutions and leveraging its scientific expertise, the company is able to develop promising medical solutions for patients with severe metabolic disorders and other conditions.

Il attesa fatturato di Viking Therapeutics ammonta a 7,17 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il attesa profitto di Viking Therapeutics ammonta a -620,18 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Viking Therapeutics è attualmente -4,91. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Viking Therapeutics.

Il rapporto prezzo/fatturato (P/S) di Viking Therapeutics è attualmente 424,99. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Viking Therapeutics.

Il Quality Score AlleAktien per Viking Therapeutics è 4/10.

L'ISIN di Viking Therapeutics è US92686J1060. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Viking Therapeutics è A12GD6. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Viking Therapeutics è VKTX. Con questo simbolo di borsa vengono negoziate le azioni Viking Therapeutics in borsa.

Valore equoTerminal
28,06 USD
Sopra-/SottovalutazioneTerminal
Correttamente valutato
Settore
Industria
Biotecnologia
Numero di azioni
Dipendenti
Crescita ricavi Ø 5 anni
Crescita EBIT Ø 5 anni
Crescita dell'utile netto Ø 5 anni
Valuta
USD
Offerta pubblica iniziale
29 apr 2015
ISIN
US92686J1060
CUSIP
92686J106
SEDOL
BQQG1V1
Capitalizzazione di mercato
Intervallo 52 settimane
AAQS
4 / 10
Rapporto PEG
—
Rapporto P/E
P/Ee 2026
-4,91
P/Ee 2027
-5,00
P/Ee 2028
-6,81
P/Ee 2029
-15,59
P/Ee 2030
16,05
P/V
P/Ve
424,99
EV/EBIT
—
Rapporto P/B
4,83
ROE (Ritorno sul capitale proprio)
ROA (Ritorno sugli attivi)
ROCE (Ritorno sul capitale investito)
ROIC (Ritorno sul capitale investito)
-56,26 %
Ultimo aggiornamento 19 nov 2026, 19:32

Viking Therapeutics Ticker

DÜSSELDORF · 1VT.DUFRANCOFORTE · 1VT.FLONDON · 0VQA.LLONDON STOCK EXCHANGE · 0VQA.LMONACO · 1VT.MUNASDAQ · VKTX

Viking Therapeutics FIGI

VKTX:US · BBG006LGV869VKTX:UA · BBG006RB1XL5VKTX:UC · BBG006RB1XM4VKTX:UN · BBG006RB1XP1VKTX:UP · BBG006RB1XQ0VKTX:UB · BBG006RB1XS8VKTX:UM · BBG006RB1XV4VKTX:UX · BBG006RB1XW3VKTX:UR · BBG006RB1XX2VKTX:UD · BBG006RB1Y24VKTX:UF · BBG006RB1Y51VKTX:VY · BBG006RB1Y60